| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.astrazenecaindia.com/india | |
| Market Cap | 13,250.00 Cr. | |
| Enterprise Value(EV) | 12,729.75 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 55.72 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 95.12 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.74 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 268.31 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 19.75 | Calculated using Price: 5,300.00 |
| Dividend Yield | 0.30 | Period Ending 2023-03 |
| No. of Shares Subscribed | 2.50 Cr. | 25,000,000 Shares |
| FaceValue | 2 | |
| About Astrazeneca Pharma India Ltd. | ||
| The Company is engaged in the business of manufacture, distribution and marketing of life-changing medicines in crucial areas of healthcare including oncology, cardiovascular, diabetes, renal, metabolic and respiratory. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC. | ||
| 1 Day |
|
+0.58% |
| 1 Week |
|
+0.22% |
| 1 Month |
|
+3.29% |
| 3 Month |
|
-17.27% |
| 6 Month |
|
+15.47% |
| 1 Year |
|
+68.24% |
| 2 Year |
|
+92.38% |
| 5 Year |
|
+135.29% |
| 10 Year |
|
+387.42% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | -12.93 | 3.43 | 10.63 | 11.12 | 20.03 | 21.83 | 22.83 | 12.78 | 18.13 | |
| Return on Capital Employed (%) | -12.93 | 3.76 | 18.74 | 18.65 | 26.53 | 34.61 | 31.24 | 17.36 | 24.49 | |
| Return on Assets (%) | -5.04 | 1.25 | 4.25 | 4.76 | 9.34 | 10.57 | 11.31 | 6.65 | 9.37 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 151 | 156 | 223 | 247 | 301 | 364 | 456 | 511 | 589 | 655 | |
| Non Curr. Liab. | 1 | 39 | 89 | 110 | 23 | 44 | 45 | 74 | 69 | -10 | |
| Curr. Liab. | 260 | 234 | 202 | 219 | 268 | 367 | 373 | 392 | 484 | 435 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 412 | 429 | 514 | 575 | 591 | 776 | 874 | 977 | 1,142 | 1,081 | |
| Non Curr. Assets | 148 | 162 | 250 | 243 | 178 | 193 | 186 | 212 | 206 | 127 | |
| Curr. Assets | 263 | 267 | 263 | 333 | 413 | 582 | 689 | 765 | 936 | 954 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 412 | 429 | 514 | 575 | 591 | 776 | 874 | 977 | 1,142 | 1,081 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 517 | 564 | 544 | 571 | 728 | 832 | 814 | 806 | 1,003 | 1,197 | |
| Other Income | 8 | 7 | 14 | 12 | 16 | 13 | 13 | 15 | 26 | 34 | |
| Total Income | 525 | 571 | 558 | 583 | 745 | 845 | 826 | 820 | 1,029 | 1,231 | |
| Total Expenditure | -531 | -547 | -507 | -525 | -657 | -711 | -678 | -719 | -838 | -1,002 | |
| PBIDT | -6 | 23 | 51 | 59 | 88 | 134 | 148 | 101 | 191 | 229 | |
| Interest | -1 | -1 | -1 | -1 | -1 | ||||||
| Depreciation | -15 | -17 | -16 | -15 | -15 | -19 | -20 | -17 | -16 | -15 | |
| Taxation | -1 | -15 | -18 | -18 | -42 | -34 | -21 | -35 | -49 | ||
| Exceptional Items | -40 | -24 | |||||||||
| PAT | -21 | 5 | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 139 | |
| Adjusted EPS | -8 | 2 | 8 | 10 | 22 | 29 | 37 | 25 | 40 | 56 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | -1 | -46 | 57 | 38 | 9 | 55 | 87 | 105 | 101 | 58 | |
| Cash Fr. Inv. | -15 | -19 | -4 | 0 | -9 | 4 | -171 | 173 | 5 | 18 | |
| Cash Fr. Finan. | 86 | -1 | -6 | -9 | -9 | -24 | |||||
| Net Change | 71 | -64 | 53 | 38 | -1 | 59 | -90 | 269 | 96 | 52 | |
| Cash & Cash Eqvt | 88 | 23 | 76 | 115 | 114 | 173 | 84 | 352 | 448 | 500 |
|
Fri, 19 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Manasa R Designation: Company Secretary EmailId: manasa.r1@astrazeneca.com Name of the Chief Financial Officer: Bhavana Agrawal Designation: Chief Financial Officer and Director EmailId: bhavana.agrawal@astrazeneca.com Date: 19/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
|||||||||||||||||||||
|
Tue, 16 Apr 2024
Certificate Under Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As required under Regulation 49(10) of SEBI (LODR) Regulations 2015 we furnish herewith a certificate issued by the Practising Company Secretary with regard to transfer of securities effected during the year ended March 31 2024. |
|||||||||||||||||||||
|
Fri, 12 Apr 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 We are enclosing herewith the Certificate dated April 5 2024 issued by the RTA of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018. |
| Thu, 25 Apr 2024 |
Closing Above Previous High
|
Making Higher Highs for 2 Days
|
High Decrease in 3 Months
|
High Increase in 1 Year
|
High Increase in 2 Years
|
